{"id":"W4378800385","doi":"10.1016/s1470-2045(23)00158-4","title":"Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval; BC Cancer Agency","funders":"National Cancer Institute; Medical Research Council; Advanced Accelerator Applications; Astellas Pharma; Clovis Oncology; AstraZeneca; National Institute for Health and Care Research; Novartis; Pfizer","keywords":"Medicine; Prostate cancer; Glutamate carboxypeptidase II; Radioligand; Quality of life (healthcare); Oncology; Internal medicine; Lutetium; Cancer; Nursing; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002030153,0.0002247172,0.002324883,0.0001518185,0.00009681976,0.00001380649,0.0001806195,0.00007089797,0.00002720294],"category_scores_gemma":[0.0004759456,0.0001205256,0.00004828301,0.0005138837,0.0004296632,0.00008193899,0.00008945658,0.0002460838,3.431076e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006714017,"about_ca_system_score_gemma":0.003380312,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002339701,"about_ca_topic_score_gemma":0.01838537,"domain_scores_codex":[0.9963483,0.001284792,0.0009586252,0.0003205982,0.0006567753,0.0004309289],"domain_scores_gemma":[0.9969084,0.001168364,0.0007547007,0.000367118,0.0006475784,0.0001538762],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9414437,0.0005027154,0.03075646,0.001715486,0.0007092972,0.00003122337,0.01459618,0.0001071773,0.00004065536,0.00003691485,0.000167615,0.009892553],"study_design_scores_gemma":[0.8982659,0.06603287,0.02142083,0.0005049818,0.0002387079,3.803966e-7,0.01300264,0.00004927728,0.0001615236,0.0000134322,0.0001804648,0.0001290225],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.985691,0.002509678,0.000003599385,0.002559098,0.0001120063,0.006672939,0.002352135,0.00001865084,0.00008089553],"genre_scores_gemma":[0.9980124,0.0007302831,0.0004011111,0.00006246586,0.00001776439,0.0003304409,0.0003715453,0.00002546982,0.00004856243],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06553015,"threshold_uncertainty_score":0.9995266,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09987168394441787,"score_gpt":0.4555469674960141,"score_spread":0.3556752835515963,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}